Navigation Links
Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
Date:3/18/2008

s is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In addition to AEG33773, Aegera has three programs in clinical development for oncology indications:

- AEG35156 targets the key anti-apoptotic protein XIAP, and is currently

in multiple Phase II human clinical trials for the treatment of solid

tumors and leukemia;

- AEG41174 is a novel, non-ATP competitive, small molecule tyrosine

kinase inhibitor targeting therapeutically significant kinases

including JAK2 and Bcr-Abl, and is currently in Phase 1 clinical

studies;

- AEG40826 (HGS1029) is a small molecule IAP inhibitor that has shown

promising preclinical activity alone and in combination with other

anti-neoplastic agents across a broad range of cancers. A license and

collaboration agreement was executed in December 2007 whereby Human

Genome Sciences, Inc. (Nasdaq: HGSI) acquired exclusive rights to

develop and commercialize small-molecule IAP inhibitors in oncology.

Website: http://www.aegera.com


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... Arlington, Massachusetts (PRWEB) October 22, 2014 ... recently announced the release of a new infographic, ... was to create a beautifully designed, easy to follow ... Ebola's transmission, areas of outbreak, symptoms and prevention. , ... have discovered that the 2014 Ebola outbreak represents not ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Biotechnology,International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the ... plants and,animals in the People,s Republic of China, today ... 2008., Third Quarter 2008 Highlights -- ... the third quarter of 2007 ...
... revenue with reduction in loss for the quarter, ... (OTC Bulletin Board: EROX) ("HPS" or "the Company") today,announced ... September 30,2008. For the three month period ending September ... from the revenues of $239,000 in the,prior year period, ...
... Driven by the human genome project, and research in the ... antibacterial, antifungal, and genetic therapeutics), world market for biotechnology reagents ... towards proteomics from genomics in the post-genome-project research period is ... years. , ...
Cached Biology Technology:Yongye Biotechnology Announces Record Third Quarter Results 2Yongye Biotechnology Announces Record Third Quarter Results 3Yongye Biotechnology Announces Record Third Quarter Results 4Yongye Biotechnology Announces Record Third Quarter Results 5Yongye Biotechnology Announces Record Third Quarter Results 6Yongye Biotechnology Announces Record Third Quarter Results 7Yongye Biotechnology Announces Record Third Quarter Results 8Yongye Biotechnology Announces Record Third Quarter Results 9Yongye Biotechnology Announces Record Third Quarter Results 10Yongye Biotechnology Announces Record Third Quarter Results 11Yongye Biotechnology Announces Record Third Quarter Results 12Human Pheromone Sciences Announces Third Quarter Results 2Human Pheromone Sciences Announces Third Quarter Results 3Human Pheromone Sciences Announces Third Quarter Results 4World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 2World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc. 3
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... Diabetes Center have found genetic regions that, when defective, allow ... a series of mis-steps that lead to type 1 diabetes. ... Immunity, the researchers are now trying to hone in on ... , “The significance of this study is that we found ...
... found to defy the most basic tenet of sexual ... sex, according to Howard Hughes Medical Institute researchers at ... 2005, issue of Nature, the researchers reported that, in ... "sex" can mate and produce offspring. Infection with the ...
... identified the proteins that allow specific brain cells to "change ... the cell. The findings, described in the March 24 issue ... day using it to protect cells that die in Lou ... what comes into the living room, these brain cells are ...
Cached Biology News:Genetic defects give the immune system the green light to attack the pancreas 2Genetic defects give the immune system the green light to attack the pancreas 3Same-Sex Mating Discovered in a Toxic Fungus 2Same-Sex Mating Discovered in a Toxic Fungus 3Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3